Vaxart (merged with Aviragen Therapeutics)

Vaxart has developed a vaccine delivery system that greatly enhances the adaptive immune response to orally delivered antigens. The vaccine system provides a key stimulatory signal (double-stranded RNA, a Toll-Like Receptor 3 ligand) for dendritic cell activation along with a viral delivery vector (rAd). Vaxart's viral vector is based on a safe, non-replicating adenovirus that expresses a key protective antigen from the target pathogen. Viral vector and TLR3 ligand are packaged in particles that...Show all

Vaxart has developed a vaccine delivery system that greatly enhances the adaptive immune response to orally delivered antigens. The vaccine system provides a key stimulatory signal (double-stranded RNA, a Toll-Like Receptor 3 ligand) for dendritic ce...Show all

See All Exits Recent Exits

Phone: 415-437-0132

Fax:

20 California Street
7th Floor
San Francisco, 94111
California, United States

Vaxart (merged with Aviragen Therapeutics) - Investments & Acquisitions

Show Real Data Vaxart (merged with Aviragen Therapeutics) Investments
See all Recent Investments
Date Company Round Amount Co-investors
See all 0 investments